Off labels refer to the act of prescribing a medicine for an indication other than a use approved by the Ministry of Food and Drug Safety. In general, the use of the drug has been determined by the health authorities, and the question may arise as to why it is necessary.

However, there is an area of disease where this Off label prescription is covered by insurance benefits. It is NMOSD. Currently, the immunosuppressant Azathioprine is used for primary maintenance treatment for optic vesical schomyelitis, and Mycophenolate or Mapthera are prescribed as the second treatment after the failure of Azachioprine treatment. Mycophenolate and Rituximab Offlabel drugs that do not have indications for o